Innovators benefit from increased momentum during technology transfer, shorter timelines, reduced risk, and lower costs. Wheeler Bio’s technology platform, Portable CMC ™, simplifies the path between drug discovery and clinical manufacturing by providing a new bridge for translating discoveries to IND filing. Wheeler’s novel hub-and-spoke operational model, centered in the biomanufacturing metro of Oklahoma City, and integrated with biotechs and discovery CROs, will revolutionize the speed of drug development. Wheeler Bio is a biomanufacturing pioneer, founded by a team of industry experts and strategic investors who believe a different CDMO model is needed to help innovators reach their clinical milestones faster. The RightSource SM Laboratory at Wheeler Bio will be operational in Q3 2023 and is anticipated to start in-process and release testing by Q4 2023. “The RightSource SM business model significantly reduces upfront lab set up costs, shields the client from the regulatory burden of managing a QC lab, and allows for leveraging our robust scientific expertise-directly where clients need it most,” said Ian Wyllie, Director Operations, RightSource SM, Charles River. ![]() Wheeler Bio’s hub-and-spoke operating model connects coastal innovators with translational CMC services that are thoughtfully aligned with clients’ business needs and fundraising strategies. Portable CMC ™ is an open-source, predictive, “CMC middleware” that efficiently bridges discovery and early development milestones. Wheeler Bio provides its clients with access to an innovative manufacturing platform called Portable CMC™, which is coupled with Leap-In Transposase® (ATUM) and a layer of digital solutions to accelerate timelines from discovery to IND. This platform-based satellite lab will be operated by Charles River employees who will utilize Charles River’s quality management systems, test methods, and standard operating procedures (SOPs) to support all QC testing needs for Wheeler Bio. Wheeler Bio and Charles River will work in close collaboration to set up a cGMP testing lab at Wheeler Bio’s ultra-modern Oklahoma City facility. “On-site support by the industry’s leading testing provider adds considerable value to our growing base of clients advancing important therapeutic antibodies and other biologics into human trials for the first time.” “We are thrilled to welcome Charles River’s RightSource SM onsite at our state-of-the-art drug substance manufacturing facility in downtown Oklahoma City,” said Jesse McCool, Co-Founder and Chief Executive Officer at Wheeler Bio. ![]() Deployed on-site at a client’s facility, RightSource SM is a flexible biologics testing lab operated and managed by Charles River, making fast, reliable quality control (QC) more accessible to a broader reach of companies like Wheeler Bio. (NYSE: CRL) today announced an agreement to implement RightSource SM at Wheeler Bio’s current good manufacturing practice (cGMP) biologics manufacturing facility in Oklahoma City, OK. ![]() OKLAHOMA CITY, OK., May 31, 2023- Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), and Charles River Laboratories International, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |